KPV Safety Profile KPV demonstrates a favorable safety profile in all preclinical studies reviewed, with no acute toxicity at therapeutic doses
Liya Kerem There have been isolated reports suggesting a link between GLP-1 receptor agonist treatment and suicidal behavior, yet no comprehensive studies have been conducted, particularly in adolescents, Liya Kerem, MD, MSc, pediatric endocrinologist at Hadassah Hebrew University Medical Center in Jerusalem, Israel, told Healio
The moment you introduce liquid, you wake them up and start the clock on their stability
Always consult the latest official prescribing information for time-sensitive medical and regulatory details.
The 7.2 mg dose was approved by the MHRA in January 2026 and represents a significant increase from the previous maximum of 2.4 mg